Product Information
JATENZO 158 MG CAPSULE is a brand product labeled by TOLMAR Inc., priced at $8.9719 per EA under NDC 69087015812. Its NADAC has been published 124 times since May 22, 2024.
FDA first approved this application on Mar 27, 2019.
Strength
158 mg/1
Manufacturer
TOLMAR Inc.NDC
69087015812
Classification
Brand
Dosage Form
CAPSULE, LIQUID FILLED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
TESTOSTERONE UNDECANOATEApproval Type
New Drug (NDA)
FDA Application
NDA206089FDA Approved
3/27/2019
On Market Since
8/1/2019
Pharmacological Classes
Price Statistics
The NADAC for JATENZO 158 MG CAPSULE has been published 124 times since May 22, 2024, and over the history we have for it it has risen 8.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $8.9719 per EA |
|---|---|
| All-time high | $8.9803 (May 13, 2026) |
| All-time low | $8.2534 (May 22, 2024) |
| 52-week high | $8.9803 |
| 52-week low | $8.6274 |
| Median price | $8.6382 |
| Average price | $8.6478 |
| Largest weekly change | +4.0% (Jan 7, 2026) |
| Weeks tracked | 124 |
| Tracking since | May 22, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the testosterone undecanoate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
TOLMAR Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
testosterone undecanoate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Androgen class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of JATENZO 158 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for JATENZO 158 MG CAPSULE, manufactured by TOLMAR Inc., is $8.9719 per EA (NDC 69087015812), effective Sep 30, 2026.
How has the price of JATENZO 158 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for JATENZO 158 MG CAPSULE has risen 8.7%. It has been tracked across 124 weekly CMS publications since May 22, 2024.
What are the highest and lowest recorded NADAC prices for JATENZO 158 MG CAPSULE?
Since May 22, 2024, the NADAC for JATENZO 158 MG CAPSULE has ranged from a low of $8.2534 (May 22, 2024) to a high of $8.9803 (May 13, 2026), with a median of $8.6382 per EA.
Are there cheaper alternatives to JATENZO 158 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of JATENZO 158 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures JATENZO 158 MG CAPSULE?
JATENZO 158 MG CAPSULE (NDC 69087015812) is labeled by TOLMAR Inc., and CMS classifies it as a brand product.